Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Neuroblastoma 2Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Lymphoma 1Hepatoblastoma 1

Interventions

plerixafor 1pazopanib 1lorukafusp alfa 1liposomal doxorubicin 1imetelstat 1Temozolomide 1Pentetic Acid 1Palliative Care 1Nutritional Support 1Minocycline 1MAGEA3 protein, human 1MAGEA1 protein, human 1Heparin 1Glutamine 1Gemcitabine 1GRN163L peptide 1Filgrastim 1Erlotinib Hydrochloride 1Electroacupuncture 1Docetaxel 1Dexamethasone 1Celecoxib 1Calcium Carbonate 1Analgesia 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Osteosarcoma × imetelstat × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡